Patent Award Spurs Rise in Nexell Shares
Dow Jones
Nexell Therapeutics Inc.’s surging stock moved up another 12% Thursday after the Irvine cancer research company said it received a patent covering in-vitro growth of specialized white blood cells to help the immune system fight bacterial infection and produce platelets to support blood clotting.
The stock, which has gained 700% so far this year, closed at $10 a share, up $1.09, in Nasdaq trading.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
